Improved detection of measurable residual disease in acute myeloid leukemia-Reference-Cited by-同舟云学术

Improved detection of measurable residual disease in acute myeloid leukemia

Published:2023-09-22 Issue:38 Volume:9 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Zhang Xuan¹^ORCID,Grimes H. Leighton¹^ORCID

Affiliation:

1. Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA.

Abstract

A novel multiplex single-cell genomic and immunophenotypic strategy leverages the sensitivity of MRD detection and distinguishes leukemic and preleukemic subpopulations.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/sciadv.adk2533

Reference3 articles.

1. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

2. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

3. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment;Cancer Letters;2024-07

2. Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives;Cancers;2024-04-15

3. The ferroptosis landscape in acute myeloid leukemia;Aging;2023-11-29

4. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them;Expert Review of Hematology;2023-11-21